Patents Assigned to Vivia Biotech S.L.
  • Patent number: 8703491
    Abstract: Disclosed herein is a sample supply device that alternates between the supply of samples from one sample line while cleaning a second sample line and then supplying a second sample from the second sample line while cleaning the first sample line. This is repeated in rapid succession to allow greater speed in analyzing a plurality of samples in a shorter amount of time.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: April 22, 2014
    Assignee: Vivia Biotech S.L.
    Inventor: Alex Okun
  • Publication number: 20130109101
    Abstract: Disclosed herein is a sample supply device that alternates between the supply of samples from one sample line while cleaning a second sample line and then supplying a second sample from the second sample line while cleaning the first sample line. This is repeated in rapid succession to allow greater speed in analyzing a plurality of samples in a shorter amount of time.
    Type: Application
    Filed: November 16, 2012
    Publication date: May 2, 2013
    Applicant: VIVIA BIOTECH S.L
    Inventor: VIVIA BIOTECH S.L
  • Patent number: 8313948
    Abstract: Disclosed herein is a sample supply device that alternates between the supply of samples from one sample line while cleaning a second sample line and then supplying a second sample from the second sample line while cleaning the first sample line. This is repeated in rapid succession to allow greater speed in analyzing a plurality of samples in a shorter amount of time.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: November 20, 2012
    Assignee: Vivia Biotech S.L.
    Inventor: Alex Okun
  • Publication number: 20100298255
    Abstract: Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.
    Type: Application
    Filed: May 19, 2010
    Publication date: November 25, 2010
    Applicant: Vivia Biotech S.L.
    Inventors: Juan Ballesteros, Teresa Bennett, Daniel Primo, Alberto Orfao, Coyt Jackson, Santiago Lago, Maria Matoses, Lilia Suarez, Sandra Sapia, Andrew Bosanquet, Julian Gorrochategui, Consuelo Tudela, Pilar Hernandez, Luis Ignacio Caveda